2nd RSC Anglo-Nordic Medicinal Chemistry Symposium


Tuesday-Friday, 11th-14th June 2019

Hotel Comwell Borupgaard, Snekkersten, Denmark


Registration is closed


Twitter hashtag - #ANMC2019


Downloads and Links

Second announcement and call for posters

First announcement


Venue website (showing location)

National travel information website

RSC website



This 2.5 day symposium followed on from the very successful inaugural meeting held in 2017 containing high quality international speakers from industry and academia on topics of Medicinal Chemistry and related enabling technologies. Organised by the Biological and Medicinal Chemistry Sector of the Royal Society of Chemistry, together with Nordic affiliates, the meeting was an exciting and invigorating gathering packed with fantastic opportunities to disseminate knowledge and expand networks.


Programme Themes and Features

The scientific programme featured themed lectures, focusing on medicinal chemistry and related technologies and disciplines across a range of drug targets and modalities. A distinguishing feature of this symposium is the collegiate style which encourages an atmosphere of information sharing and learning.

The event included first rate lectures, poster session, trade exhibition, ample networking opportunities, welcome buffet on Tuesday, exceptional location, venue and accommodation.


Who should attend

Medicinal chemists at all career stages. Scientists with an interest in drug discovery or new technologies that can be applied to the drug discovery process.


Call for Posters

The call for posters is closed.  Papers were invited for poster presentation and the closing date was 30th April 2019.  Some posters were selected for flash oral presentation.


The call for oral abstracts closed on 31st October 2018.


Full Programme

Where presentation titles are highlighted thus, you may download the .pdf


Tuesday, 11th June


Welcome reception, registration, and buffet dinner




Wednesday, 12th June





Session 1 - Translational Regulation

Session chair - Malin Lemurell, AstraZeneca, Sweden


Opening remarks

Adrian Hall, UCB, Belgium, and Member of the Organising Committee


Keynote:  Translating RNA sequence into lead small molecule medicines

Matthew Disney, Scripps Research, USA


Optimising PROTACs towards the clinic: turning promises of low dose and long duration into reality

Ian Smith, GlaxoSmithKline, UK


Refreshments, exhibition and posters


Discovery and characterization of highly potent and selective allosteric USP7 inhibitors
Colin O'Dowd, Almac Discovery, UK


Rewriting the (tran)script: discovery of Risdiplam

Hasane Ratni, Roche, Switzerland


Lunch, exhibition and posters



Flash Poster Presentations Session

Session chairs - Malin Lemurell, AstraZenecca, Sweden, and Morten Jørgensen, Lundbeck, Denmark

Download the flash poster presentation programme here




Dedicated poster session, refreshments thereafter

14.00Prosecution of the cyclin dependent kinase (CDK) family using NanoBRET intracellular engagement to examine clinically relevant inhibitors for target occupancy and residency time measurements in living cells
Gary Allenby, Aurelia Bioscience, UK (C01)
14.02Understanding the role of free-ligand conformations and protein plasticity upon Mcl-1 inhibition
Michael Bodnarchuk, AstraZeneca, UK (C02)
14.04Capturing and applying knowledge to guide compound optimisation
Edmund Champness, Optibrium, UK (C03)
14.06Design, synthesis and evaluation of novel autotaxin inhibitors
Jennifer Clark, University of Strathclyde, UK (C04)
14.08The synthesis and evaluation of the physicochemical properties of nitrogen containing 6,5-bicyclic heterocycles
Brett Cosgrove, GlaxoSmithKline, UK (C05)
14.10Structure-based design and synthesis of novel hydroxamates as dual targeting inhibitors
Ehab Ghazy, Martin Luther University of Halle Wittenberg, Germany (C07)

PhABits – PhotoAffinity Bits to study protein-ligand binding
Emma Grant, GlaxoSmithKline, UK (C08)

Poster prize-winner - People's Prize

14.14High quality estimates of key human clinical ADME/PK parameters directly from chemical structure
Sven Hellberg, Prosilico, Sweden (C09)
14.16Nanocyclix: next generation kinase therapeutics: a chemocentric approach for the discovery of selective kinase inhibitors
Christopher Housseman, Oncodesign, France (C10)
14.18Macrolide inspired macrocyclic library: from design to biological evaluation
Goran Kragol, Fidelta, Croatia (C11)
14.20Engineering bicyclic small molecule heterocycles as anti-malarial therapeutics: design, synthesis and biological studies
Mrinal Kundu, TCG Lifesciences, India (D14)
14.22The discovery of a potent and orally bioavailable macrocyclic cyclophilin inhibitor based on the structural simplification of Sanglifherin A
Linos Lazarides, Eurofins Selcia Drug Discovery, UK (D16)
Joint poster prize-winner - Judges' Prize
14.24Rational design, synthesis and biological profiling of new JMJD2C inhibitors
Vatroslav Letfus, Fidelta, Croatia (C12)
14.26Development of Aquaporin 9 inhibitors – a novel mechanism for treatment of diabetes
Kristoffer Peterson, Red Glead Discovery, Sweden (D18)
14.28Fragment screening of USP7 by weak affinity chromatography (WAC™)
Kirill Popov, Red Glead Discovery, Sweden (D19)
14.30Integrating experimental and computational pharmacology for intelligent drug design
Susanne Roth, InterAx Biotech, Switzerland (D21)
14.32Fragment-based discovery of catalytic LSD1 inhibitors with SPR
Rajiv Sawant, Beactica, Sweden (D22)
14.34DIdentification of modulators of the insulin receptor/ IGF1 receptor dimer as a treatment for type 2 diabetes
Katie Simmons, University of Leeds, UK (D24)
14.36Capsule chemistry at the touch of a button – a new tool for medicinal chemistry
Benedikt Wanner, Synple Chem, Switzerland (C13)
14.38Tankyrase inhibitor development: evidence for potential in cancer immune therapy – an update
Anita Wegert, Mercachem, TheNetherlands (D26)


Session 2 - Enabling Science and Technologies I

Session chair - Adrian Hall, UCB, Belgium


Late stage functionalisation of drug candidates using PolyCYPs® enzymes

Frank Scheffler, Hypha Discovery, UK


Can a computer design a drug?
John Cumming, pRED, F Hoffmann-La Roche, Switzerland


Identification of nanomolar inhibitor of RuvBL1/2 from DNA-encoded small molecule library
Iolanda Micco, Vipergen ApS, Denmark





Thursday, 13th June



Session 3 - Enabling Science and Technologies II

Session chair - Morten Jørgensen, Lundbeck, Denmark

09.00Keynote:  Prodrug strategies in medicinal chemistry
Jarkko Rautio, University of Eastern Finland, Finland


Structurally enabled discovery of innovative Calcitonin Gene-Related Peptide (CGRP) receptor antagonists
Steve Watson, Heptares, UK


Refreshments, exhibition and posters


Lowering lipophilicity by adding carbon - building bridges to improve physicochemical properties of drug molecules
Sébastien Degorce, AstraZeneca, UK


HIV nucleoside reverse transcriptase translocation inhibitors to enable extended duration dosing

Izzat Raheem, MSD, USA


Lunch, exhibition and posters

Poster session kindly sponsored by Enamine




Session 4 - Drug Design Disclosures I

Session chair - Sharan Bagal, AstraZeneca, UK


Discovery of GLPG2451, a novel potentiator for the treatment of cystic fibrosis
Steven van der Plas, Galapagos, Belgium


The Lundbeck approach to FBDD in the CNS drug space - from weak fragments to the PDE1 inhibitor development candidate

Mauro Marigo, Lundbeck, Denmark


Discovery of novel pyrido[2,3-b]pyrazine based small molecule pan-Fibroblast Growth Factor Receptor (FGFR) inhibitors and optimization into a potential clinical candidate
Patrick Angibaud, Janssen, France


Refreshments, exhibition and posters


Discovery of AZD5718, a novel 5-lipoxygenase activating protein (FLAP) inhibitor currently in Ph2 for treatment of Coronary Artery Disease (CAD)
Daniel Pettersen, AstraZeneca, Sweden


Identification of a novel oxadiazole RORg antagonist – a balancing act
Morten Dahl Sørensen, LEO Pharma, Denmark



Conference dinner


Friday, 14th June



Session 5 - Drug Design Disclosures II

Session chair - Sharan Bagal, AstraZeneca, UK


Target validation with chemical probes: reproducing pharmacology and safety aspects of the phenotype of Rorc-deficient mice with RORC2 inverse agonists in rats

Samuel Hintermann, Novartis, Switzerland


Discovery of the TYK2 selective inhibitor PF-6826647 for the treatment of Crohn’s disease, and other autoimmune conditions
Brian Gerstenberger, Pfizer Inc, USA


Refreshments, exhibition and posters


Discovery of the oral LTC4S inhibitor AZD9898 as a new treatment for asthma
Lena Ripa, AstraZeneca, Sweden


Discovery of H3B-8800, a novel, orally bioavailable, small molecule, splice modulator

Andrew Cook, H3 Biomedicine, USA


Resetting the antibacterial arms race: LepB as a novel gram negative target

James Crawford, Genentech, USA


Closing remarks

Sharan Bagal, AstraZeneca and Chair of the Organising Committee, UK


Lunch and depart


Registration, Fees, and Bursaries

The previous meeting was very popular and oversubscribed such that capacity was increased to 140 attendees for 2019. Discounted rates were offered to RSC members and limited student bursaries were available.

Registration fees included the Tuesday evening welcome buffet.

Early rates for payments received by 22nd March
£525 RSC member
£605 Non-member
£400 RSC student* member
£440 Student* non-member

Standard rates for payments received between 23rd March and 10th May
£575 RSC member
£655 Non-member
£450 RSC student* member
£490 Student* non-member

Late rates for payments received from 11th May onwards
£55   Late payment fee was added to the above standard rates

* Student is undergraduate or post-graduate, not post-doc, and does not apply to students in paid employment.
Member is paid-up member of the RSC.

Some student bursaries were available for this meeting (funded by the RSC-BMCS). The closing date for applications was 16th April. 


Cancellation Policy

In the event of cancellation by 26th May, 80% of the fee paid will be refunded. Cancellations must be received in writing. Refunds will not be possible after that date although substitutions are possible at any time. Dinners and Accommodation Packages will only be refunded (in line with the policy above) if the room can be resold.  In the unlikely event of cancellation of the meeting, fees paid will be refunded in full. Acknowledgements will be sent within two weeks.


Exhibition stands were priced at £1,100, and this fee included for one full delegate with access to the technical programme.


Each exhibitor stand comprised a space measuring 1.5 metres wide with electricity and a table measuring 1.5 m wide x 0.75 m deep x 0.72 m high.


Delegate pack inserts could be booked at £275 (sponsor to supply), comprising no more than two pages of A4 fixed together.



The accommodation and dinners package was priced at £585, and  comprised:
- three nights’ bed and breakfast accommodation at the conference Hotel Comwell Borupgaard (from Tuesday to Thursday inclusive)
- three-course dinner with drinks on Wednesday
- conference dinner with drinks on Thursday
It was advisable to book this at the time of registration.


Venue and Travel

Address:  Hotel Comwell Borupgaard, Nørrevej 80, Snekkersten 3070, Denmark


Travel (with guide prices - please check for yourself): 

By train:  55 minutes from Copenhagen airport/railway station to Snekkersten.   Cost £10-£17

By taxi:  45 minutes from Copenhagen airport/railway station to Snekkersten.  Cost £95-£100

By bus and train:  1h 50m from Copenhagen airport/railway station to Snekkersten.  Cost £7-£20



A location map may be found here

A map with travel modes and charges from Copenhagen station may be found here.

National travel information website



We are grateful to our confirmed sponsors, AstraZeneca, LEO Pharma, Lundbeck, and Vipergen for their valued support.



Organising Committee

Sharan Bagal (chair)AstraZeneca, UK
Kevin N DackLEO Pharma, DK
Adrian HallUCB, BE
Morten JørgensenLundbeck, DK
Malin LemurellAstraZeneca, SE


Secretariat Contact

Maggi Churchouse Events, 3 East Barn, Market Weston Road, Thelnetham, Diss IP22 1JJ, UK


Telephone: +44 (0)1359 221004


Registration is closed